Promotion of Anagen, Increased Hair Density, and Reduction of Hair Fall in a Clinical Setting Following Identification of FGF5-Inhibiting Compounds via a Novel 2-Stage Process

In 2017, researchers conducted a study to identify FGF5-inhibiting compounds that could prolong the anagen phase of hair growth and reduce hair loss. They discovered monoterpenoid compounds with significant FGF5 inhibitory activity and conducted a clinical trial with 32 participants over 112 days. The trial, which was randomized, single-blind, and placebo-controlled, showed that topical formulations containing the compound MTP3 led to significant improvements in the anagen:telogen ratio, reduced hair fall, and increased hair density. The 0.095% MTP3 formulation was particularly effective, suggesting potential for future hair loss treatments. The study concluded that MTP3 is a potent FGF5 inhibitor and can improve hair growth metrics in individuals with early- to mid-stage pattern hair loss.